Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections)

Journal of Neuroimmunology

Volumn 147, Issue 1-2, 2004, Pages 43-49

  Ringheim, Garth E ^a   Conant, Katherine ^b  

^a SANOFI   (France)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Neurodegeneration; Neuroimmune axis; Parkinson's disease

Indexed keywords

ALZHEIMER DISEASE; BRAIN INFECTION; CELL FUNCTION; CELL LOSS; CELL SURVIVAL; CLINICAL FEATURE; CONFERENCE PAPER; DEGENERATIVE DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOMODULATION; NERVE CELL LESION; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 1642493596     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.10.013     Document Type: Conference Paper

References (81)

1. Abbas N., Bednar I., Mix E., Marie S., Paterson D., Ljungberg A., Morris C., Winblad B., Nordberg A., Zhu J. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J. Neuroimmunol. 126:2002;50-57.
2. Blasko I., Marx F., Steiner E., Hartmann T., Grubeck-Loebenstein B. TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J. 13:1999;63-68.
3. Blasko I., Veerhius R., Stampfer-Kountchev M., Saurwein-Teissl M., Eikelenboom P., Grubeck-Loebentein B. Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol. Dis. 7:2000;682-689.
4. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172:1994;151-154.
5. Breitner J.C.S., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Perciak-Vance M.A., Saunders A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging. 16:1995;523-530.
6. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's brain: central role for amyloid β-peptide. Trends Mol. Med. 7:2001;548-554.
7. Casamenti F., Prosperi C., Scali C., Giovannelli L., Colivicchi M.A., Faussone-Pellegrini M.S., Pepeu G. Interleukin-1β activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease. Neuroscience. 91:1999;831-842.
8. Chao C.C., Hu S., Kravitz F.H., Tsang M., Anderson W.R., Peterson P.K. Transforming growth factor-β protects human neurons against β-amyloid-induced injury. Mol. Chem. Neuropathol. 23:1994;159-178.
9. Colton C.A., Needham L.K., Brown C., Cook D., Rasheed K., Burke J.R., Strittmatter W.J., Schmechel D.E., Vitek M.P. APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J. Nueroimmunol. 147:2004;62-67. (this issue).
10. DeGiorgio L.A., Shimizu S.Y., Chun H.S., Cho B.P., Sugama S., Joh T.H., Volpe B.T. APP Knockout Attenuates Microglial Activation and Enhances Neuron Survival in Substantia Nigra Compacta After Axotomy. Glia. 38:2002;174-178.
11. Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56:1997;321-339.
12. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.H., Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. 7:1993;75-83.
13. Duffy P.E., Rapport M., Graf L. Glial fibrillary acidic protein and Alzheimer-type senile dementia. Neurology. 30:1980;778-782.
14. Epstein L.G., Gendelman H.E. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann. Neurol. 33:1993;429-436.
15. Factor S.A., Sanchez-Ramos J., Weiner W.J. Trauma as an etiology of parkinsonism: a historical review of the concept. Mov. Disord. 3:1988;30-36.
16. Fine S.M., Angel R.A., Perry S.W., Epstein L.G., Rothstein J.D., Dewhurst S., Gelbard H.A. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J. Biol. Chem. 271:1996;15303-15306.
17. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81:2002;1285-1297.
18. Garlind A., Brauner A., Höjeberg B., Basun H., Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res. 826:1999;112-116.
19. Giulian D., Haverkamp L.J., Yu J.H., Karshin W., Tom D., Li J., Kirkpatrick J., Kuo L.M., Roher A.E. Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J. Neurosci. 16:1996;6021-6037.
20. Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L. III, Araoz C. Brain interleukin1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 86:1989;7611-7615.
21. Griffin W.S., Sheng J.G., Roberts G.W., Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54:1995;276-281.
22. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8:1998;65-72.
23. Guillemin G.J., Croitoru-Lamoury J., Dormont D., Armati P.J., Brew B.J. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia. 41:2003;371-381.
24. He Y., Appel S., Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909:2001;187-193.
25. Herkenham M., Lee H.Y., Baker R.A. Temporal and spatial patterns of c-fos mRNA induced by intravenous interleukin-1: a cascade of non-neuronal cellular activation at the blood-brain barrier. J. Comp. Neurol. 400:1998;175-196.
26. Huell M., Strauss S., Volk B., Berger M., Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. 89:1995;544-551.
27. Iravani M.M., Kashefi K., Mander P., Rose S., Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience. 110:2002;49-58.
28. Ishizuka K., Kimura T., Igata-Yi R., Katsuragi S., Takamatsu L., Mikakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatr. Clin. Neurosci. 51:1997;135-138.
29. Kerr D.A., Larsen T., Cook S.H., Fannjiang Y.R., Choi E., Griffin D.E., Hardwick J.M., Irani D.N. BCL-2 and BAX protect adult mice from lethal Sindbis virus infection but do not protect spinal cord motor neurons or prevent paralysis. J. Virol. 76:2002;10393-10400.
30. Klegeris A., McGeer P.L. β-Amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J. Neurosci. Res. 49:1997;229-235.
31. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygeneases-1 and -2. Mol. Cell. Neurosci. 16:2000;724-739.
32. Koh J.Y., Yang L.L., Cotman C.W. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
33. Lahiri D.K., Nall C. Promoter activity of the gene encoding the β-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Mol. Brain Res. 32:1995;233-240.
34. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339:1998;1044-1053.
35. Li Y., Liu L., Liu D., Woodward S., Barger S.W., Griffin W.S.T. Microgial activation by uptake of FDNA via a scavenger receptor. J. Neuroimmunol. 147:2004;50-55. (this issue).
36. Ling Z., Gayle D.A., Ma S.Y., Lipton J.W., Tong C.W., Hong J.S., Carvey P.M. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov. Disord. 17:2002;116-124.
37. Liu B., Du L., Hong J.S. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide. J. Pharmacol. Exp. Ther. 293:2000;607-617.
38. Liu B., Qin L., Yang S.N., Wilson B.C., Liu W., Hong J.S. Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage. J. Pharmacol. Exp. Ther. 298:2001;1133-1141.
39. Lorenzo A., Yankner B.A. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12243-12247.
40. Lu J., Chua H.H., Chen S.Y., Chen J.Y., Tsai C.H. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res. 63:2003;256-262.
41. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
42. McGeer P.L., Yasojima K., McGeer E.G. Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease. Neurosci. Lett. 326:2002;67-69.
43. Meda L., Bonaiuto C., Szendrei G.I., Ceska M., Rossi F., Cassatella M.A. β-Amyloid (25-35) induces the production of interleukin-8 from human monocytes. J. Neuroimmunol. 59:1995;29-33.
44. Meda L., Baron P., Prat E., Scarpini E., Scarlato G., Cassatella M.A., Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with β-amyloid[25-35]. J. Neuroimmunol. 93:1999;45-52.
45. Mirza B., Hadberg H., Thomsen P., Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience. 95:2000;425-432.
46. Njenga M.K., Marques C., Rodriguez M. The role of cellular immune response in Theiler's virus-induced central nervous system demyelination. J. Neuroimmunol. 147:2004;73-77. (this issue).
47. Noris E., Zannetti C., Demurtas A., Sinclair J., De Andrea M., Gariglio M., Landolfo S. Cell cycle arrest by human cytomegalovirus 86-kDa IE2 protein resembles premature senescence. J. Virol. 76:2002;12135-12148.
48. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
49. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13:1993;1676-1687.
50. Pulliam L., Gascon R., Stubblebine M., McGuire D., McGrath M.S. Unique monocyte subset in patients with AIDS dementia. Lancet. 349:1997;692-695.
51. Rampe D., Wang L., Ringheim G.E. P2X7 receptor modulation of h-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. J. Neuroimmunol. 147:2004;. (this issue).
52. Ringheim G.E., Burgher K., Yamdagni P., Aschmies S., Paul J.W., Cai J. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain. J. Neuroimmunol. 63:1995;113-123.
53. Ringheim G.E., Szczepanik A.M., Burgher K.L., Petko W., Heroux J.A., Cavalieri F. Transcriptional inhibition of the Alzheimer's disease β-amyloid precursor protein by interferon-gamma. Biochem. Biophys. Res. Commun. 224:1996;246-251.
54. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
55. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336:1997;1216-1222.
56. Sasaki A., Yamaguchi H., Ogawa A., Sugihara S., Nakazato Y. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol. (Berl.). 94:1997;316-322.
57. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766.
58. Sheng J.G., Mrak R.E., Griffin W.S. S100β protein expression in Alzheimer's disease: potential role in the pathogenesis of neuritic plaques. J. Neurosci. Res. 39:1994;398-404.
59. Sheng J.G., Mrak R.E., Griffin W.S. Microglial interleukin-1α expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathol. Appl. Neurobiol. 21:1995;290-301.
60. Sheng J.G., Mrak R.E., Griffin W.S. Enlarged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain. Acta Neuropathol. 95:1998;229-234.
61. Smith M.A., Harris P.L.R., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:1997;2653-2657.
62. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16:2002;1474-1476.
63. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
64. Sundstrom J.B., Mosunjac M., Martinson D.E., Bostik P., Donahoe R.M., Gravanis M.B., Ansari A.A. Effects of norepinephrine, HIV type 1 infection, and leukocyte interactions with endothelial cells on the expression of matrix metalloproteinases. AIDS Res. Hum. Retrovir. 17:2001;1605-1614.
65. Szczepanik A.M., Funes S., Petko W., Ringheim G.E. IL-4, IL-10 and IL-13 modulate Aβ(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol. 113:2001;49-62.
66. Szczepanik A.M., Rampe D., Ringheim G.E. Amyloid-β peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem. 77:2001b;304-317.
67. Tavares R.G., Tasca C.I., Santos C.E.S., Alves L.B., Porciuncula L.O., Emanuelli T., Souza D.O. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 40:2002;621-627.
68. Thibeault I., Laflamme N., Rivest S. Regulation of the gene encoding the monocyte chemoattractant protein 1 (MCP-1) in the mouse and rat brain in response to circulating LPS and proinflammatory cytokines. J. Comp. Neurol. 434:2001;461-477.
69. Van Muiswinkel F.L., Veerhuis R., Eikelenboom P. Amyloid β protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. J. Neurochem. 66:1996;2468-2476.
70. Veldman B.A., Wijn A.M., Knoers N., Praamstra P., Horstink M.W. Genetic and environmental risk factors in Parkinson's disease. Clin. Neurol. Neurosurg. 100:1998;15-26.
71. Vos C.M., Gartner S., Ransohoff R.M., McArthur J.C., Wahl L., Sjulson L., Hunter E., Conant K. Matrix metalloprotease-9 release from monocytes increases as a function of differentiation: implications for neuroinflammation and neurodegeneration. J. Neuroimmunol. 109:2000;221-227.
72. Wallace M.N., Geddes J.G., Farquhar D.A., Masson M.R. Nitric oxide synthase in reactive astrocytes adjacent to β-amyloid plaques. Exp. Neurol. 144:1997;266-272.
73. Wang T., Liu B., Qin L., Wilson B., Hong J.-S. Protective effect of the SOD/catalase mimetic MnTMPyP on inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuroglia cultures. J. Neuroimmunol. 147:2004;68-72. (this issue).
74. Wegiel J., Wang K.C., Imaki H., Rubenstein R., Wronska A., Osuchowski M., Lipinski W.J., Walker L.C., LeVine H. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol. Aging. 22:2001;49-61.
75. Widner B., Leblhuber F., Walli J., Tilz G.P., Demel U., Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 107:2000;343-353.
76. Williams K.C., Hickey W.F. Traffic of hematogenous cells through the central nervous system. Curr. Top. Microbiol. Immunol. 202:1995;221-245.
77. Wisniewski H.M., Wegiel J., Wang K.C., Kujawa M., Lach B. Ultra-structural studies of the cells forming amyloid fibers in classical plaques. Can. J. Neurol. Sci. 16:1989;535-542.
78. Xia M.Q., Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J. Neurovirol. 5:1999;32-41.
79. 1-42- and lipopolysaccharide-activated microglia. J. Neurosci. 22:2002;3484-3492.
80. Yasuhara O., Matsuo A., Terai K., Walker D.G., Berger A.E., Akiguchi I., Kimura J., McGeer P.L. Expression of interleukin-1 receptor antagonist protein in post-mortem human brain tissues of Alzheimer's disease and control cases. Acta Neuropathol. (Berl.). 93:1997;414-420.
81. Yoshida T., Tanaka M., Suzuki Y., Sohmiya M., Okamoto K. Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats. Neurosci. Lett. 330:2002;1-4.